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Abstract 
Objective - Ibrutinib is an irreversible Btk inhibitor approved for treatment of Waldenstrom’s 
macroglobulinemia, chronic lymphocytic leukemia and mantle cell lymphoma that increases 
the risk of bleeding among patients. Platelets from ibrutinib-treated patients exhibit 
deficiencies in collagen-evoked signaling in suspension, however the significance of this 
observation and how it relates to bleeding risk is unclear, as platelets encounter immobile 
collagen in vivo. We sought to clarify the effects of ibrutinib on platelet function to better 
understand the mechanism underlying bleeding risk. 
Approach and Results - By comparing signaling in suspension and during adhesion to 
immobilised ligands we found that the collagen signaling deficiency caused by ibrutinib is 
milder during adhesion to immobilised collagen. We also found that platelets in whole blood 
treated with ibrutinib adhered to collagen under arterial shear but formed unstable thrombi, 
suggesting that the collagen signaling deficiency caused by ibrutinib may not be the 
predominant cause of bleeding in vivo. However, clot retraction and signaling evoked by 
platelet adhesion to immobilised fibrinogen were also inhibited by ibrutinib, indicating that 
integrin αIIbβ3 outside-in signaling is also effected in addition to GPVI signaling. When 
ibrutinib was combined with the P2Y12 inhibitor, cangrelor, thrombus formation under arterial 
shear was inhibited additively. 
Conclusions - These findings suggest that (1) ibrutinib causes GPVI and integrin αIIbβ3 
platelet signaling deficiencies that result in formation of unstable thrombi and may contribute 
toward bleeding observed in vivo and (2) combining ibrutinib with P2Y12 antagonists, which 
also inhibit thrombus stability, may have a detrimental effect on hemostasis. 
 
  
3 
 
Introduction  
Ibrutinib is an inhibitor of the Tec family kinase, Bruton’s tyrosine kinase (Btk) approved for 
the treatment of chronic lymphocytic leukemia, mantle cell lymphoma and Waldenstrom’s 
macroglobulinemia. Patients receiving ibrutinib exhibit deficiencies in hemostasis, resulting 
in incidents of bruising and petechiae in up to 48% of patients and grade 3 or greater 
bleeding in 5% of patients.1 Platelets from patients receiving ibrutinib exhibit deficient 
responses to collagen and the GPVI-specific agonist, CRP-XL.2-4 However, responses to 
other platelet agonists such as ADP and U46619 are unaffected or only mildly inhibited.2 Btk 
is a critical component of the signaling pathway of the GPVI collagen receptor and ibrutinib 
appears to inhibit collagen-evoked signaling via inhibition of Btk.4 However, the effects of 
ibrutinib have predominantly been investigated using platelet suspension assays, while the 
impact of ibrutinib on adhesion and signaling on immobilised ligands has not been explored 
but may be more representative of the platelet environment in vivo. The distinction between 
suspension and adhesion may be critical to understanding the underlying mechanism of 
haemostatic dysfunction caused by ibrutinib. 
The involvement of Btk in GPVI-evoked platelet signaling was first identified when patients 
suffering from X-linked agammaglobulinemia, caused by a deficiency in Btk, were found to 
have platelets with impaired responses to collagen.5 However, the contribution of Btk to the 
GPVI signaling pathway is partially redundant to the closely related kinase, Tec as only 
simultaneous knockout of both Tec and Btk renders mouse platelets insensitive to CRP-XL.6 
X-linked agammaglobulinemia patients do not exhibit a platelet-dependent bleeding 
phenotype, which contrasts with the enhanced bleeding risk among patients receiving 
ibrutinib and suggests that Tec may also be inhibited by clinically relevant concentrations of 
Ibrutinib. Following activation of the platelet GPVI receptor, Btk and Tec are activated 
downstream of Syk, Fyn and Lyn and regulate PLCγ2 activation, and thereby Ca2+ release 
and PKC activation which are critical events in platelet activation.6, 7 In addition to GPVI, 
platelets also express α2β1 and the GPIb receptor complex that can mediate adhesion to 
collagen and generate intracellular signaling that supports haemostatic platelet function.8 Btk 
has an established role in the signaling pathway evoked by GPIb9 and consequent inhibition 
of adhesion to vWF in the presence of ibrutinib has been reported.4 The role of Btk in α2β1-
mediated signaling is less clear, as is the ability for α2β1 to function in the absence of 
signaling evoked by GPVI,8 making the effects of ibrutinib on collagen-evoked adhesion and 
signaling under shear difficult to predict. 
The role of Btk may not be limited to collagen and vWF-evoked pathways, as integrin αIIbβ3-
evoked outside-in signaling is believed to share many features of the GPVI signaling 
pathway, although conflicting reports regarding the involvement of Btk in outside-in signaling 
have been published. A study reporting that phosphorylation of Btk occurs following direct 
activation of integrin αIIbβ3 with MnCl2 in mouse and human platelets suggests the 
involvement of Btk in outside-in signaling.10 However it has also been reported that mouse 
platelets with simultaneous deficiency of both Btk and Tec adhere and spread normally on 
fibrinogen.6 Overall the role of Btk in integrin αIIbβ3 outside-in signaling is unclear. The effect 
of Ibrutinib on integrin outside-in signaling has not previously been explored but offers an 
opportunity to investigate the role of Tec family kinases in such signaling in human platelets. 
It is possible that inhibition of integrin αIIbβ3 outside-in signaling may play a role in bleeding 
risk as mice with genetically modified β3, harbouring tyrosine substitutions in the cytoplasmic 
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tale that ablate outside-in signaling, have a mild bleeding phenotype characterised by poor 
clot stability that results in re-bleeding.11 
To improve understanding of the effects of ibrutinib on platelet function we performed a 
comparison of the effects of ibrutinib on platelet signaling in suspension and during adhesion 
to immobilised ligands. Using this strategy we identified key differences that suggested that 
the previously reported loss of platelet collagen sensitivity may not cause a deficiency in 
adhesion to immobile collagen. Further investigation revealed that initial adhesion to 
collagen under arterial shear was not inhibited by ibrutinib, however, ibrutinib caused 
instability and disaggregation of thrombi. This lead us to investigate positive feedback 
signaling that supports thrombus stability and the subsequent finding that ibrutinib causes 
inhibition of outside-in signaling evoked by integrin αIIbβ3. Because of the important role of 
integrin αIIbβ3 outside-in signaling in clot stabilisation, inhibition of this pathway in addition to 
GPVI signaling may be an important factor in the bleeding caused by ibrutinib. 
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Materials and Methods 
Materials and Methods are available in the online-only Data Supplement. 
Results 
Ibrutinib inhibits CRP and collagen-evoked [Ca2+]i elevation and aggregation in 
suspension 
Platelet function has been measured in blood taken from patients receiving 560 mg of 
Ibrutinib daily and responses to collagen and CRP were found to be inhibited, however, the 
effect of ibrutinib on platelet signaling and adhesion to immobile collagen has not been 
measured.3, 4 To provide a comparison of the effects of ibrutinib on platelet signaling  in 
suspension and during adhesion we first investigated the effects of ibrutinib on elevation of 
[Ca2+]i and aggregation in evoked by collagen, CRP-XL, ADP and U46619 in suspension. At 
concentrations of up to 1 µM, Ibrutinib inhibited Ca2+ elevation evoked by collagen and the 
GPVI agonist, CRP-XL but not ADP or U46619 (Figure 1A). Aggregation evoked by collagen 
or CRP-XL was completely inhibited by 1µM ibrutinib (figure 1B). However, aggregation 
evoked by ADP was only mildly inhibited (12.7 ± 5.5% inhibition) and the kinetics of U46619-
evoked aggregation was often slowed and appeared biphasic although the trend did not 
reach statistical significance at 5 minutes (Figure 1B). The lack of effect of ibrutinib upon 
ADP and U46619-evoked [Ca2+]i elevation suggests that the observed trend toward mild 
inhibition of aggregation, which has also been noted in other studies,2, 4 may indicate 
inhibition of positive feedback signaling, such as integrin αIIbβ3 outside-in signaling. 
Inhibition of GPVI-evoked signaling caused by ibrutinib is concentration-dependent 
within the range of clinically relevant concentrations 
We employed [Ca2+]i quantification and plate-based aggregometry, to define the 
concentration dependency of platelet inhibition caused by ibrutinib (Figure 2). Ibrutinib 
inhibited [Ca2+]i elevation evoked by 1 µg/ml CRP-XL with an IC50 of 51 nM ± 10.7 while half-
maximal inhibition of aggregation was only achieved at  186 nM ± 81.2 (Figure 2A-B). We 
found that the concentration-dependent component of the inhibition curves covered the 
range of peak serum concentrations measured clinically in patients receiving 560mg ibrutinib 
daily (mean ≈ 300 nM).12 This suggests that variability in plasma concentration may cause 
large differences in platelet inhibition among patients. 
Ibrutinib is an irreversible inhibitor of Btk13 and therefore expected to exhibit insurmountable 
inhibition with limited or no dependence on stimulus strength. However, a positive correlation 
between log[CRP-XL] and logIC50 was identified, and may be indicative of ibrutinib 
interacting with more than one target with different affinities (Figure 2C-D). It is tempting to 
speculate that these targets may represent the two Tec family kinases expressed by 
platelets, Btk and Tec, both of which are inhibited by ibrutinib.13 However, we were unable to 
blot to determine the relative phosphorylation of these two Tec family kinases to investigate 
this further. 
Ibrutinib inhibits signaling evoked by GPVI downstream of PLCγ2 
Ibrutinib is an inhibitor of other kinases in addition to Btk, including Src family kinases (SFKs) 
and Tec,13 which could contribute toward the observed platelet inhibition. Although ibrutinib 
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has been screened for activity against a panel of kinases, the screen was performed in a 
cell-free in vitro assay and the estimated IC50 values do not appear to correlate closely with 
the potency of ibrutinib observed in vivo or ex vivo. We found that ibrutinib inhibits Src 
phosphorylation at Y418 with an IC50 of 2.0 µM ± 1.05 (Figure 3A-B), which was 20 fold 
higher than that required for half-maximal inhibition of [Ca2+]i elevation (IC50 = 51 nM ± 10.7) 
evoked by the same concentration of CRP-XL (Figure 2A). Phosphorylation of Syk was not 
inhibited by 1 µM ibrutinib, (174% ± 54 relative to control, Figure 3D) a concentration that 
ablated both [Ca2+]i elevation and aggregation evoked by 1 µg/ml CRP-XL. Taken together, 
these observations suggest that the potent inhibition of GPVI signaling caused by ibrutinib is 
not attributable to inhibition of SFKs. In contrast to measurements of Src and Syk 
phosphorylation, 1 µM ibrutinib was found to ablate PLCγ2 tyrosine phosphorylation as well 
as total ser/thr phosphorylation of all substrates of PKC (Figure 3E-F). Measurement of p-
selectin exposure and fibrinogen binding that are representative of the downstream 
signalling events of granule secretion and integrin αIIbβ3 activation were also inhibited by 1 
µM ibrutinib (Figure 3G). Btk/Tec forms part of the PLCγ2 activation complex down stream of 
GPVI and therefore inhibition of PLCγ2, PKC and [Ca2+]i elevation are consistent with a 
Btk/Tec-dependent mode of action. To investigate the effects of ibrutinib in subsequent 
experiments a concentration of 1µM was used, to ensure that complete inhibition of platelet 
function mediated by GPVI was achieved. 
Ca2+ signaling evoked by adhesion to immobilised collagen is only partially inhibited 
by ibrutinib 
To understand the significance of the collagen and CRP-XL specific inhibition caused by 
ibrutinib in suspension, we studied the effects of ibrutinib on platelet function during 
adhesion to immobilised ligands. Platelet adhesion and activation on immobilised collagen is 
thought to be orchestrated by GPVI which triggers activation, integrin α2β1 which supports 
adhesion, and GPIb which, via the interaction with vWF ensures initial adhesion to collagen 
under arterial shear.8 While GPVI has the most established role in mediating collagen-
evoked intracellular signaling, integrin α2β114 may also be capable of initiating signaling. The 
effects of ibrutinib on adhesion to immobile collagen were therefore difficult to predict, but 
may be significant in understanding the mechanism by which it causes bleeding. We found 
that adhesion of platelets to immobilised CRP-XL was inhibited by 70% ± 13.9 in the 
presence of 1 µM ibrutinib (Figure 4Ai-ii). Spreading under these conditions was also 
strongly inhibited where the proportion of platelets exhibiting lamellipodia was reduced from 
69% ± 5.3 to 11% ± 4.8 in the presence of 1 µM ibrutinib (Figure 4Aiii). The efficacy of 
ibrutinib as an inhibitor of platelet function mediated by GPVI therefore appeared to be 
maintained in spreading experiments. Adhesion to CRP-XL appeared to be dependent upon 
activation which was blocked by ibrutinib. CRP-XL is not an adhesive ligand and adhesion to 
CRP-XL may be therefore be reliant on deposition of adhesive proteins present in α-
granules such as vWF and fibrinogen that are secreted upon activation.15 In contrast, 
adhesion to type I collagen was not significantly inhibited by the presence of 1µM ibrutinib 
relative to control (100% ± 2.5, Figure 4Aii). Spreading and formation of lamellipodia on 
collagen was significantly inhibited in the presence of ibrutinib (48% ± 8.9 expressing 
lamellipodia in the presence of vehicle compared to 33% ± 6.6 with 1 µM ibrutinib) but to a 
lesser extent than on CRP-XL (Figure 4Aiii). The differential effects of ibrutinib on adhesion 
and spreading on immobilised collagen and CRP-XL suggest that Btk-independent signaling 
may be stimulated by adhesion to collagen.  
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To explore the apparent differences in the effects of ibrutinib during stimulation with 
immobilised or solubilised collagen, we investigated signaling evoked by adhesion to type I 
collagen. Ibrutinib reduced PLCγ2 phosphorylation by 84% relative to control whereas it was 
ablated by dasatinib (Figure 4B), a kinase inhibitor that targets SFKs and causing platelet 
inhibition and bleeding side effects in patients.16 Total ser/thr phosphorylation of all PKC 
substrates, which lie downstream of PLCγ2 were also partially inhibited by ibrutinib (76% ± 
9.8 relative to control) and strongly inhibited by dasatinib (5% ± 0.6 relative to control). We 
used single cell imaging to measure [Ca2+]i in individual platelets as they came into contact 
with type I collagen-coated cover glass in the presence or absence of ibrutinib or dasatinib. 
Unlike the complete ablation observed when platelets were stimulated with collagen in 
suspension (Figure 1A), [Ca2+]i elevation was only partially inhibited by ibrutinib during 
adhesion to immobilised collagen (50% ± 8.1 of vehicle response, Figure 4Cii). In the 
presence of ibrutinib the sustained [Ca2+]i elevation evoked by collagen in the majority of 
platelets was replaced by ‘ragged’ [Ca2+]i spiking (supplementary video 1) more commonly 
associated with weaker agonists such as ADP (Figure 4Ci).17 In contrast, the SFK inhibitor 
dasatinib caused complete inhibition of [Ca2+]i elevation evoked by immobilised collagen (9% 
± 8.7 of vehicle response, Figure 4Cii). Taken together, this suggests that signaling 
stimulated by adhesion to collagen is not potently inhibited by ibrutinib. This contrasts 
directly with the total inhibition caused by ibrutinib following stimulation with collagen in 
suspension observed in this study (Figure 1-2) and others.3, 4 We suggest that signalling 
initiated by adhesion to collagen differs fundamentally to that in suspension and the role of 
btk and the effects of ibrutinib also differ under these conditions. 
Platelets adhere to collagen but do not form stable thrombi under arterial shear 
following treatment with ibrutinib 
As we had identified key differences between the effects of ibrutinib on platelet function in 
suspension and during adhesion to immobilised collagen we investigated further using an in 
vitro thrombus formation assay to assess whether the remaining collagen-mediated signaling 
of ibrutinib-treated whole blood could support thrombus formation on type I collagen under 
arterial shear conditions. Following treatment with 1 µM ibrutinib levels of thrombus 
formation after 10 minutes were significantly inhibited relative to control (39% ± 9.2 of 
vehicle-treated controls, Figure 5Bi-ii). However, surface coverage was not significantly 
reduced by ibrutinib (96% ± 12.2 of vehicle-treated controls, Figure 5C). This suggests that 
although collagen-evoked signaling via GPVI is effectively ablated by this concentration of 
ibrutinib in other assays, the remaining signaling evoked by collagen is sufficient to support 
adhesion. Despite this, thrombus stability appeared to be affected by ibrutinib resulting in 
disaggregation of growing thrombi following initial stable adhesion of platelets to collagen 
(Supplementary video 2). To test whether ibrutinib might be inhibiting secretion of secondary 
mediators such as ADP, the P2Y12 inhibitor cangrelor was tested alone and in combination in 
the same thrombus formation assay. When platelets were treated with 1 µM cangrelor, 
thrombus formation was inhibited (51% ± 12.9 of vehicle-treated controls, Figure 5B) 
whereas surface coverage was not (113% ± 19.6 of vehicle-treated controls, Figure 5C). 
Similar to the effect of ibrutinib, cangrelor did not affect initial adhesion to collagen but did 
inhibit stable thrombus formation. However, while cangrelor treatment resulted in 
embolization of ‘clumps’ of platelets from growing thrombi, ibrutinib caused disaggregation of 
individual platelets (Supplementary video 2). When ibrutinib and cangrelor treatments were 
combined, thrombus formation was more strongly inhibited (24% ± 6.0 of vehicle-treated 
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controls, Figure 5B) than by cangrelor treatment alone (although the difference was only 
significant at intermediate time points, one-way ANOVA with Bonferroni post test, p < 0.05 
after 7 minutes) while surface coverage was not significantly reduced (79 % 18.9 of vehicle-
treated controls, Figure 5C). These findings suggested that stimulation of P2Y12 by secreted 
ADP was still occurring in the presence of ibrutinib and that blockade using cangrelor 
resulted in further inhibition of thrombus stability. The comparison with cangrelor also 
highlighted that the effects of the two inhibitors were similar and both caused decreased 
thrombus stability rather than a defect in initial adhesion to collagen. 
Ibrutinib inhibits outside-in signaling mediated by integrin αIIbβ3  
It has already been established that ibrutinib does not inhibit signaling evoked by secreted 
secondary mediators that support thrombus growth and stability, therefore to explore the 
unexplained effects of ibrutinib on thrombus stability we investigated integrin αIIbβ3 outside-in 
signaling. Binding of fibrinogen to integrin αIIbβ3 evokes outside-in signaling that supports 
adhesion and spreading on immobilised fibrinogen. The physiological role of outside-in 
signaling is to provide positive feedback for platelet-activating stimuli and support clot 
retraction. We investigated outside-in signaling evoked during adhesion and spreading on 
immobilised fibrinogen to explore whether the inhibitory mechanism of ibrutinib lies in the 
disruption of the outside-in signaling pathway which has been reported to involve Btk.10 
Phosphorylation of β3 Y773 (83% ± 14.26), one of the critical tyrosine residues in the human 
β3 cytoplasmic domain for initiation of outside-in signaling,11 and Src Y418 (77% ± 20.3) 
were not significantly altered relative to vehicle treated control following adhesion to 
fibrinogen in the presence of 1 µM ibrutinib (Figure 6A). This suggested that early stages in 
the outside-in signaling pathway are unaffected by ibrutinib. We measured Ca2+ signaling 
evoked by integrin αIIbβ3 using live imaging of intracellular fluo 4 in individual platelets 
adhering to and spreading on fibrinogen (supplementary video 3). The sustained [Ca2+]i 
oscillations observed in the majority of adhered platelets was strongly inhibited by 1µM 
ibrutinib resulting in significantly lower area-under-the-curve measurements relative to 
control (Figure 6B). We also measured adhesion and spreading of platelets on fibrinogen-
coated coverglass and  found that adhesion was inhibited by 48% ± 5.4 in the presence of 1 
µM ibrutinib and the proportion of platelets forming lamellipodia was reduced (36% ± 5.6 
compared to 79% ± 8.9 in the presence of vehicle, Figure 6C). Finally, Ibrutinib also inhibited 
the process of thrombin-stimulated clot retraction, which is stimulated by integrin αIIbβ3 
outside-in signaling, by 110% ± 32.4 (relative to vehicle treated mean clot weight measured 
after 2 hours, Figure 6D). Taken together, these experiments provide evidence that ibrutinib 
affects outside-in signaling evoked by integrin αIIbβ3 resulting in inhibition of [Ca2+]i elevation 
and the processes of platelet spreading and clot retraction.  
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Discussion 
Pharmacological inhibition of the kinase Btk, has proven to be a successful therapeutic 
strategy for the treatment of B-cell based cancers and the irreversible Btk inhibitor ibrutinib 
has been approved by the FDA to treat mantle cell lymphoma, chronic lymphocytic leukemia 
and Waldenstrom’s macroglobulinemia. However, ibrutinib treatment is associated with 
increased risk of bleeding among patients. Until the present study the effects of ibrutinib on 
platelet function have predominantly been investigated using aggregation assays and other 
techniques performed in suspension. Aggregation assays constitute a critical clinical and 
diagnostic tool that aid investigation of platelet-based bleeding disorders. However, 
aggregometry has limited utility in that it does not replicate platelet thrombus formation on 
immobile surfaces in vivo. Adhesion-based platelet function assays such as the PFA-100 are 
frequently employed but have limited sensitivity18 and consequently more sophisticated in 
vitro thrombus formation assays have been developed to enhance diagnosis of platelet 
disorders.19 In the present study the effects of ibrutinib in assays performed in suspension 
and during adhesion to immobilised collagen were compared to provide a better 
understanding of how ibrutinib causes platelet signaling deficiencies and how these may 
impact upon hemostasis. 
The bleeding associated with ibrutinib has been correlated with its inhibitory effects on 
collagen-mediated platelet aggregation.2-4 We found that although ibrutinib caused potent 
inhibition of aggregation and [Ca2+]i elevation in suspension, that even at a concentration (1 
µM) that exceeds plasma concentrations measured clinically, ibrutinib did not completely 
inhibit adhesion to or signaling evoked by immobilised collagen. Although PLCγ2 activation 
in the presence of ibrutinib was markedly reduced, Ca2+ signaling and PKC substrate 
phosphorylation was less strongly inhibited. This may be indicative of signal amplification 
mediated by secretion of secondary mediators that act via PLCβ to activate PKC and 
release Ca2+. Furthermore, initial adhesion to collagen under arterial shear stress was not 
significantly inhibited by ibrutinib, while stable thrombus formation was strongly inhibited. 
This unexpected finding suggested that the mechanism underlying platelet dysfunction 
caused by ibrutinib might involve multiple signaling pathways. We and others2-4 have 
demonstrated that signaling evoked by secondary mediators is largely unaffected by 
ibrutinib, and we found that signaling via the ADP receptor, P2Y12 still occurs in the presence 
of 1 µM ibrutinib. We therefore looked to other sources of positive feedback signaling that 
contribute toward stable thrombus formation and found that outside-in signaling evoked by 
integrin αIIbβ3 was inhibited by ibrutinib. Ibrutinib inhibited integrin αIIbβ3 outside-in signaling 
via a similar mechanism to GPVI signaling where it prevented PLCγ2 activation and Ca2+ 
elevation. This is consistent with studies that have shown that btk is activated downstream of 
αIIbβ3 following direct activation with MnCl2.10 Initial events in the outside-in signaling cascade 
such as phosphorylation of β3 (Y773) and src were not significantly inhibited by ibrutinib 
suggesting they lie upstream of PLCγ2 activation when platelets are activated by contact 
with immobile fibrinogen. In a study that employed a mouse model lacking integrin αIIbβ3 
outside-in signaling due to substitution of critical tyrosine residues in the β3 cytoplasmic tail, 
the outside-in signaling deficiency was found to cause re-bleeding in tail bleed 
experiments.11 It is possible that inhibition of integrin αIIbβ3 outside-in signaling mediated by 
ibrutinib has similar effects in patients and therefore may have a role in causing bleeding. 
Interestingly, the effects of ibrutinib on thrombus formation under arterial shear were similar 
to the inhibition caused by cangrelor, which caused embolization of thrombi. However, 
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ibrutinib appeared to cause disaggregation of individual platelets from growing thrombi rather 
than embolization and inhibited thrombus stability additively with cangrelor, suggesting that 
the effects were mediated via distinct mechanisms. 
We suggest that ibrutinib causes a combination of platelet function defects via inhibition of 
Btk and Tec, and support for this hypothesis is found by comparing the bleeding phenotype 
of patients receiving ibrutinib to those of patients with disorders affecting Btk or GPVI 
function. Patients suffering from the Btk deficiency disorder, X-linked agammaglobulinemia 
are not at increased risk of bleeding because platelet Tec expression, which is unaffected, 
contributes signaling that overlaps that of Btk.6, 20 Ibrutinib inhibits Tec in addition to Btk but 
with lower potency13 and this may explain the difference in bleeding phenotype between X-
linked agammaglobulinemia patients and patients treated with ibrutinib. We found evidence 
that ibrutinib inhibits at least two targets with distinct potencies downstream of GPVI that 
may represent the two Tec family kinases expressed by platelets. Despite strong evidence 
that ibrutinib causes a GPVI-specific platelet signaling defect, bleeding observed in patients 
does not correlate wholly with the reported bleeding phenotype of individuals lacking 
functional GPVI. Although patients with GPVI signaling deficiencies frequently present with 
petechiae,21 which is also observed in patients receiving ibrutinib, lack of GPVI function is 
normally associated with only a mild bleeding defect.22-24 Interestingly, platelets with 
dysfunctional GPVI often display markedly impaired adhesion to immobilised collagen,21 
whereas this was not the case following ibrutinib treatment in the present study. This 
suggests that components of the GPVI signaling pathway that are not dependent upon Btk 
may be able to contribute toward adhesion to immobilised collagen via synergy with 
signaling evoked by secondary mediators or other adhesive receptors. 
The mechanism underlying adhesion, secretion of secondary mediators and thrombus 
formation on immobilised collagen in the presence of ibrutinib is unclear given the critical 
role of GPVI-evoked signaling in this process. Multiple platelet membrane proteins underlie 
adhesion and signaling in response to collagen. The major role of GPVI lies in initiating 
intracellular signaling while GPIb and integrin αIIbβ3 mediate adhesion to collagen via vWF. 
The integrin α2β1 mediates adhesion directly to collagen and is believed to be capable of 
initiating intracellular signaling, although evidence also exists that the affinity for collagen 
must first be enhanced via intracellular signaling mediated by another receptor.25 The 
contribution of α2β1 to collagen-evoked platelet activation is only apparent during adhesion to 
immobilised collagen and not in suspension either in vitro14 or in vivo following injection of 
mice with soluble collagen.26 This correlates with the observed effect of ibrutinib which 
inhibits collagen-mediated platelet signaling and aggregation in suspension but only partially 
inhibits signaling and thrombus formation on immobilised collagen. However, further 
investigation is required to identify the collagen receptor capable of initiating signaling in 
response to collagen in the presence of ibrutinib. 
Our study has demonstrated that platelet aggregometry does not provide an accurate means 
of identifying the nature of platelet function deficiency caused by some drugs, such as 
ibrutinib, due to the critical differences between the contribution of some signaling pathways 
in suspension and during adhesion to immobilised substrates. By utilising techniques that 
enabled us to study platelet function during adhesion we came to the conclusion that 
ibrutinib causes a combination of platelet functional defects which result in unstable 
thrombus formation in vitro and may cause bleeding in vivo. The inhibition of GPVI-evoked 
signaling caused by ibrutinib does not ablate collagen-evoked signaling or adhesion but may 
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reduce platelet activation and integrin αIIbβ3 inside-out signaling. In addition, integrin αIIbβ3 
outside-in signaling is inhibited by ibrutinib, removing a critical source of positive feedback 
signaling that supports clot stabilisation. The combined effects of ibrutinib on inside-out 
activation of integrin αIIbβ3 and outside-in signaling may therefore account for its effects on 
hemostasis. The success of ibrutinib may stimulate the development of other drugs that 
target kinases for treatment of cancers and these new drugs, like ibrutinib and dasatinib, 
may have off-target effects on hemostasis. It is therefore critical to understand how new 
kinase inhibitors affect platelet function and hemostasis. With improved understanding of the 
mechanism by which new kinase inhibitors like ibrutinib cause disruption of hemostasis may 
come the ability to improve the safety profile of future cancer drugs, predict contraindications 
or even investigate new potential anti-platelet drug targets.  
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Significance 
Ibrutinib is known to cause bleeding among patients receiving the drug but the role of 
platelet function deficiencies caused by ibrutinib downstream of GPVI are unclear. We have 
demonstrated that ibrutinib affects multiple platelet signalling pathways causing both a partial 
inhibition of collagen-evoked signalling during adhesion but also a strong inhibition of 
integrin αIIbβ3 outside in signaling that results in the formation of unstable thrombi that 
disaggregate under shear. These defects are likely to play a role in bleeding risk among 
patients receiving ibrutinib and have implications for dosing and contraindications with drugs 
such as P2Y12 antagonists that we found to have an additive effect on thrombus stability. A 
better understanding of how new drugs that target kinases modulate platelet function and 
hemostasis is critical to improving the safety of current drug strategies and future drug 
development. 
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Figure Legends 
Figure 1: Ibrutinib inhibits Ca2+ elevation and aggregation evoked by CRP-XL and collagen. For 
[Ca2+]i measurements and aggregometry washed platelets (loaded with fura-2 for [Ca2+]i 
measurements) were pre-treated with 1 µM ibrutinib or vehicle for 5 minutes and stimulated with 1 
µg/ml type I collagen, 1 µg/ml CRP-XL, 10 µM ADP or 1 µM U46619. (Ai) Shows representative [Ca2+]i 
traces and (Aii) mean peak [Ca2+]i increases normalised to % of vehicle response ± s.e.m (n=4). (Bi) 
Shows representative aggregation traces and (Bii) mean light transmission 5 minutes after addition 
of agonist ± s.e.m (n=4). * p < 0.05, **** p < 0.0001 using one-way ANOVA with a Bonferroni post 
test. 
Figure 2: Ibrutinib inhibits GPVI-evoked signaling with potency that is partially dependent upon 
stimulus strength. [Ca2+]i measurements and aggregations were performed using washed platelets 
(loaded with fura-2 for [Ca2+]i measurements) pre-treated for 5 minutes with ibrutinib at the 
indicated concentrations and stimulated with a range of CRP-XL concentrations between 10 µg/ml 
and 10 ng/ml CRP-XL or vehicle only. Average concentration responses (A) expressed as the peak 
increase in [Ca2+]i or (B) % light transmission after 5 minutes of platelet aggregation are means ± 
s.e.m. (n=4). The relationship between the stimulating [CRP-XL] and apparent IC50 of ibrutinib in Ca2+ 
(C) and aggregation (D) assays are derived from the curves presented in (A) and (B) respectively and 
are mean ± s.e.m. (n=4). Correlation between the apparent IC50 of ibrutinib and CRP-XL 
concentration was tested using Pearson’s correlation test and found to be significant (p < 0.05) for 
both [Ca2+]i increase (r=0.93) and aggregation (r=0.97). 
Figure 3: Inhibition of GPVI-evoked signaling occurs at the level of PLCγ2 activation. (A) Washed 
platelets were pre-treated for 5 minutes with a range of concentrations of ibrutinib or vehicle before 
stimulation with 1 µg/ml CRP-XL for one minute before immunoblotting for Src Y418. (B) The mean 
relative phosphorylation levels of Src Y418 ± s.e.m. (normalised to total Src) (n=4). (C) Washed 
platelets were pre-treated for 5 minutes with 1 µM ibrutinib or vehicle before stimulation with 1 
µg/ml CRP-XL for one minute, samples were blotted for Ser/Thr phosphorylation of PKC substrates 
or used for immunoprecipitation of Syk or PLCγ2 and blotted for tyrosine phosphorylation (using 
4G10 antibody). Bar charts are mean normalised phosphorylation values ± s.e.m for (D) tyrosine 
phosphorylation of Syk normalised to total Syk (E) tyrosine phosphorylation PLCγ2 relative to total 
PLCγ2 and (F) total serine /threonine phosphorylation of substrates of PKC relative to actin. (n=3). 
(G) Flow cytometry measurements of fibrinogen binding and p-selectin exposure following 
treatment of platelets for minutes with 1µg/ml CRP-XL in the presence or absence of 1µM ibrutinib 
(n=4).  * p < 0.05, ** p < 0.01, *** p < 0.001 using one-way ANOVA with a Bonferroni post test. 
Figure 4: Signaling and adhesion evoked by immobilised collagen is only partially inhibited by 
ibrutinib and ablated by dasatinib. (Ai) Washed platelets were pre-treated for 5 minutes with 1µM 
ibrutinib or vehicle and allowed to adhere to type I collagen or CRP coated cover glass for 45 
minutes. (Aii)The relative percentage of adhered platelets relative to vehicle treated (Aiii) and the 
percentage of platelets that had formed lamellapodia were quantified as mean % ± s.e.m (n=5). (Bi) 
Washed platelets were pre-treated for 5 minutes with 1 µM ibrutinib or vehicle and allowed to 
adhere to type I collagen-coated plates for 30 mins before platelets were lysed and probed for PLCγ2 
phosphorylation and phosphorylation of PKC substrates. Bar chats are mean normalised 
phosphorylation values ± s.e.m for (Bii) tyrosine phosphorylation of PLCγ2 relative to total PLCγ2 and 
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(Biii) serine /threonine phosphorylation of substrates of PKC relative to actin. (n=5). (C) PRP was 
loaded with fluo 4-AM and imaged at 1Hz during adhesion and spreading on type I collagen-coated 
cover glass under static conditions for 15 minutes in the presence of 1 µM ibrutinib, 1 µM dasatinib 
or vehicle only. (Ci) The traces are fluorescence intensity plots representative of between 10-60 
adhered platelets measured in each of 3 different donors, (Cii) bar charts are mean area-under-the-
curve (AUC) measurements ± s.e.m. (n=3). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 
using one-way ANOVA with a Bonferroni post test. 
Figure 5: Ibrutinib inhibits stable thrombus formation but not adhesion to immobilised collagen. 
(A) Thrombus formation was measured using whole blood in pre-incubated for 5 minutes with 1 µM 
ibrutinib and / or 1 µM cangrlor or vehicle only before perfusion through a type I collagen-coated 
channel for 8 minutes. Images are representative fluorescence intensity plots after 7 minutes and 
traces are (Bi) mean fluorescence intensity of thrombi with (Bii) bar charts of mean fluorescence 
intensity ± s.e.m after 10 minutes and (Ci) traces of mean surface coverage with (Cii) bar charts of 
mean surface coverage ± s.e.m after 10 minutes. (n=4). ** p < 0.01, *** p > 0.001, **** p < 0.0001 
using one-way ANOVA with a Bonferroni post test. 
Figure 6: Signaling and adhesion mediated by integrin αIIbβ3 and clot retraction are inhibited by 
ibrutinib. (Ai) Washed platelets were pre-treated for 5 minutes with 1 µM ibrutinib or vehicle and 
allowed to adhere to fibrinogen-coated plates for 30 mins before platelets were lysed and probed 
for β3 Y773 and Src Y418 phosphorylation. (Aii) Bar charts are mean normalised phosphorylation 
values  for β3 Y773 (relative to total β3) and Src Y418 (relative to 14-3-3) ± s.e.m. (n=3). (B) PRP was 
loaded with fluo 4-AM and imaged at 1Hz during adhesion and spreading on fibrinogen-coated cover 
glass under static conditions for 25 minutes in the presence of 1 µM ibrutinib or vehicle only. (Bi) The 
traces are fluorescence intensity plots representative of 10-60 adhered platelets measured in each 
of 3 donors. (Bii) Bar charts are mean area-under-the-curve (AUC) measurements ± s.e.m. (Ci) 
Washed platelets were pre-treated for 5 minutes with 1 µM ibrutinib or vehicle as indicated in the 
Figure and allowed to adhere to fibrinogen coated cover glass for 45 minutes. (Cii) The relative 
percentage of adhered platelets relative to vehicle treated and (Ciii) the percentage of platelets that 
had formed lamellipodia were quantified as mean % ± s.e.m (n=5). (Di) A representative image of 
clot retraction assessed using PRP treated with vehicle or 1µM ibrutinib 2h after addition of 1 U/ml 
thrombin, (Dii) bars represent mean clot weight ± s.e.m (n=6). * p < 0.05, *** p < 0.001, **** p < 
0.0001 using one-way ANOVA with a Bonferroni post test. 
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Materials and methods 
Materials and reagents 
Type I Collagen was obtained from Nycomed (Munich, Germany) and collagen-related peptide (CRP-
XL) from Professor Richard Farndale (University of Cambridge, Cambridge, UK). ADP, U46619, aspirin 
and thrombin was from Sigma (Gillingham, UK). Ibrutinib and dasatinib were from Selleckchem 
(Munich, Germany). Cangrelor was kindly provided by The Medicines Company (Parsippany, NJ). 
Antiphosphotyrosine antibody 4G10 was obtained from Millipore (Massachusetts, USA). PLCγ2 Q20, 
Syk 4D10, β3 N20, actin C11 and 14-3-3 antibodies were from Santa Cruz Biotechnology (Heidelberg, 
Germany). PKC substrate antibody was from New England Biolabs (Hitchin, UK). P-Src 418 antibody 
and Fura-2 AM was from Life Technologies (Paisley, UK). Y773 β3 antibody was from Abcam 
(Cambridge, UK). 
Platelet preparation 
Blood was drawn from healthy donors that had given informed consent and using procedures 
approved by the University of Reading Research Ethics Committee and collected into 50 ml syringes 
containing 4% (w/v) sodium citrate and acid citrate dextrose (ACD, 2.5% sodium citrate, 2% D-
glucose and 1.5% citric acid). PRP was prepared by centrifugation of whole blood at 100g for 20 
mins. Washed platelets were prepared by centrifugation of PRP at 350g for 20 mins, the platelet 
pellet was resuspended in Tyrodes containing 0.4 U/ml apyrase. 
Plate-based platelet aggregation 
PRP or washed platelets at a concentration of 4x108 cells/ml were loaded onto 96-well plates 
(Greiner) and treated with inhibitors or vehicle for 5 mins at 37oC prior to addition of agonist. Plates 
were shaken at 1,200 rpm for 5 mins at 37oC using a plate shaker (Quantifoil Instruments) as 
described by Lordkipanidzé et al. 1 and absorption of 405 nm light measured using a NOVOstar plate 
reader (BMG Labtech). 
Light transmission aggregometry 
Washed platelets at a concentration of 4x108 cells/ml were treated with inhibitors or vehicle for 5 
mins at 37oC prior to addition of agonist. Light transmission as measured for 5 mins using an optical 
aggregometer (Chronolog). 
Clot retraction 
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The retraction of clots formed in PRP pre-incubated for 5 minutes with 1 µM ibrutinib or vehicle and 
stimulated with 1 U/mL thrombin for 2 h at room temperature was assayed by measurement of clot 
weight. 
Immunoprecipitation and phosphorylation studies 
Washed platelets were incubated with ibrutinib or vehicle for 5 mins at 37oC prior to addition of 1 
ug/ml CRP. Samples were shaken at 1,200 rpm for 1 min at 37oC using a plate shaker (Quantifoil 
Instruments) prior to addition of reducing Laemmli sample treatment buffer. 
Single platelet Ca2+ imaging 
Platelets were loaded with Fluo 4 by incubating human PRP for 1h at room temperature with 2µM 
Fluo 4 AM. The platelets were then spun at 350 g for 10 minutes and resuspended in Tyrodes at a 
concentration of 4x108 cells/ml. The washed platelet suspension was then seeded onto fibrinogen or 
type I collagen coated coverslips (100µg/ml) at a density of 4x107 cells/ml and imaged at a rate of 1 
Hz using the 60 x oil immersion lens and 488nm laser of a Nikon A1-R Confocal microscope.  
FACs  
Flow cytometry was performed in 96-well platelets. Platelets at 2x107 cells/ml were stimulated with 
1µg/ml CRP-XL at room temperature for 20 minutes in the presence of fluorescein isothiocyanate-
labelled (FITC) anti-fibrinogen antibody and PE/Cy5 anti-human CD62P (P-selectin). Reactions were 
stopped by with 0.2% (v/v) paraformaldehyde. Flow cytometric acquisition was performed using a 
BD Accuri C6 flow cytometer (BD Biosciences, Oxford, UK), and data were collected from 10,000 
events and analysed using the CFlow Sampler software as described previously.   
Spreading studies 
Washed platelets were exposed to fibrinogen (100 µg/ml) or type I collagen (100 µg/ml) coated 
coverslips and left to incubate for 45 minutes at 37°C. Non-adherent platelets were removed, and 
the coverslips washed three times with PBS, before fixing using 0.2% paraformaldehyde solution for 
10 minutes. The coverslips were then washed and treated with 0.1% (v/v) Triton-X to permeabilise 
the platelets.  The Triton-X was then removed and coverslips washed three times before staining 
with phalloidin-Alexa Fluor 488 for 1 hr in the dark at room temperature. Coverslips were then 
further washed in PBS and mounted onto microscope slides. Adherent platelets were then imaged 
with a 100x oil immersion lens on a Nikon A1-R Confocal microscope.  
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Adhesion data in each experiment was obtained by counting the number of platelets on 5 images of 
each coverslip that were chosen at random. The platelets scored as being non-spread, spreading 
(extending filopodia) and fully spread (formation of lamellipodia) and the relative frequency of these 
were determined.  
In vitro thrombus formation 
Thrombus formation was studied in vitro using microfluidic flow cells (Vena8, CellixLtd, Dublin, 
Ireland) and type I collagen as described previously.2 
Measurement of [Ca2+]i  
Platelets were loaded with Fura-2 by incubating PRP with 2 µM Fura-2 AM for 1h at 30oC. Platelets 
were then washed by centrifugation at 350 g for 20 mins and resuspended in Tyrodes containing 0.4 
U/ml apyrase. Fura-2 loaded platelets were incubated with inhibitors or vehicle for 5 mins at 37oC 
prior to addition of agonists. Fluorescence measurements with excitation at 340 and 380 nm and 
emission at 510 nm were recorded over a period of 5 mins using a NOVOstar plate reader (BMG 
Labtech). [Ca2+]i  was estimated using the ratio of the 340 and 380 nm excited signals, the method of 
Grynkiewicz et al was utilised.3 The maximum fluorescence ratio was measured by lysing the cells 
with 50 µM digitonin which released the Fura-2 into the saline containing 2 mM CaCl2. The minimum 
fluorescence ratio was measured by chelating Ca2+ ions with 10 mM EGTA and 10 mM TRIS base to 
ensure that the pH remained alkaline for optimum Ca2+ buffering by EGTA. The autofluorescence 
was measured using cells at the same final concentration which had not been loaded with fura-2. 
The following equation was then used to calculate experimental [Ca2+]i  concentrations using the 
calibration values acquired as described above: 
[𝐶𝑎2+]𝑖 =  𝐾𝑑  ×
𝑆𝑓
𝑆𝑏
 ×  
𝑅 −  𝑅𝑚𝑖𝑛
𝑅𝑚𝑎𝑥 − 𝑅
 
Where Kd is the dissociation constant of Fura-2 (224 nM). Sf and Sb are the background-corrected 
values of the fluorescence at 380 nm excitation, with zero or saturating Ca2+ respectively. R is the 
background-corrected 340/380 nm fluorescence ratio and Rmin and Rmax are the ratio limits at zero or 
saturating Ca2+ respectively, which have been adjusted using a viscosity constant of 0.85 which 
corrects for the effects of the cellular environment upon Fura-2 fluorescence.4 
 
Statistical analysis 
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Prism v.6 (Graphpad, La Jolla, CA) was used to perform statistical analysis and to generate graphs. 
Statistical comparisons were tested using one-way analysis of variance (ANOVA) and p-values were 
generated using the Bonferroni multiple comparisons test. 
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